子痫前期早期预测及杞菊地黄口服液对子痫前期的预防作用研究  

Early Prediction of Preeclampsia and the Preventive Effect of Qiju Dihuang Oral Liquid on Preeclampsia Patients:a Clinical Study

作　　者：张莹艳 王琪[2] 

机构地区：[1]北京市怀柔妇幼保健院妇产科,北京101400 [2]首都医科大学附属北京妇产医院产科,北京100026

出　　处：《中国中西医结合杂志》2013年第12期1645-1647,共3页Chinese Journal of Integrated Traditional and Western Medicine

摘　　要：目的 研究子痫前期发病风险评估系统在筛查子痫前期高危符合率，探讨杞菊地黄口服液对子痫前期的预防作用。方法 对2000名妊娠16~20周孕妇采用随机抽样法分为A组和B组，每组1 000名，分别采用子痫前期发病风险评估和平均动脉压法预测子痫前期发病率，将200例预测子痫前期发病高危孕妇，分为对照组及治疗组，每组100例，两组均进行常规治疗。治疗组加用杞菊地黄口服液，每次10 mL，每日2次。每月连续服药2周，观察2周，连续6个疗程或按疗程至终止。观察并比较两组发病率。结果 子痫前期发病风险评估系统的预测符合率为72.3%，高于平均动脉压法50.5%，对比差别显著（P〈0.05）；治疗组发病率（32.0%）低于对照组（46.0%），差异均有统计学意义（P〈0.05）。结论 子痫前期高危因素评估法准确性较高，杞菊地黄口服液干预治疗可降低子痫前期发病率。Objective To study the clinical value of the preeclampsia risk assessment system, and to explore the preventive effect of Qiju Dihuang Oral Liquid （QDOL） on preeclampsia patients. Methods Totally 2 000 pregnant women in the gestational week 16 -20 were equally assigned to Group A and Group B by randomized sampling. Their preeclampsia incidence was respectively assessed by preeclampsia risk assessment system and mean arterial pressure method. Of them, 200 pregnant women at predicted high risk of preeclampsia were assigned to the control group and the treatment group, 100 in each group. All re- ceived routine treatment. Patients in the treatment group additionally took QDOL, 10 mL each time, twice daily;2 consecutive weeks per month for totally 2 weeks; lasting for six consecutive courses or ending according to the therapeutic course. The incidence was observed and compared between the two groups. Results The predicted coincidence rate of the risk assessment system was 72.3%, higher than that of mean arterial pressure method （50.5%, P 〈0.05）. The incidence rate of the treatment group was 32.0%, lower than that of the control group （46.0%, P 〈0.05）. Conclusions The preeclampsia risk assessment system was more accurate. QDOL could lower the incidence of preeclampsia as intervention.

关 键 词：子痫前期 杞菊地黄口服液 高危评分 

分 类 号：R714.245[医药卫生—妇产科学]